Dr Adam M Hill, CEO of Oncimmune, said: "Following last week's announcement of the publication of the ECLS trial in the European Respiratory Journal, we are delighted to see these additional abstracts presented online.

"Beyond proving the ability of the EarlyCDT Lung blood test to detect cancer earlier in a screening population, it is also important to assess the negative impacts of using the test in the population, and the costs of implementing the diagnostic. These findings will no doubt assist our ongoing commercial discussions with health authorities in the UK and in other territories, and we look forward to the peer reviewed publications in due course."